Frontlight ResearchEarly access
Active, not recruitingPhase 3
A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
Key facts
- Who runs it
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 526 people enrolled
- Started
- 13 May 2022
- Ended
- Dec 2025
- Type of study
- Interventional, 3 groups
- Treatments tested
- Lower dose atropine sulfate eye drops
- Low dose atropine sulfate eye drops
- placebo
- Record updated
- 30 July 2025
Who can take part
- Age
- 6 years to 10 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- Child (female or male) aged 6 to 10 years
- Myopia (SER of at least -0.50 D and no more myopic than -6.00 D) in each eye as measured by cycloplegic autorefraction
- If present, astigmatism of ≤1.50 D in each eye as measured by cycloplegic autorefraction
- Anisometropia SER of < 1.50 D as measured by cycloplegic autorefraction
Who cannot take part
- Chronic use of any topical or systemic antimuscarinic/anticholinergic medications (e.g.,atropine, scopolamine, tropicamide) within 21 days prior to screening and/or anticipated need for chronic use during the study period (i.e., more than 7 consecutive days in 1 month or more than 30 total days in 1 year); Use of cycloplegic drops for dilated ocular exam was allowable
- History of any disease or syndrome that predisposed the subject to severe myopia (e.g.,Marfan syndrome, Stickler syndrome, retinopathy of prematurity)
- Heart rate persistently (for more than 10 minutes) > 120 beats per minute
- Allergy to study drugs
- History in either eye of abnormal ocular refractive anatomy (e.g., keratoconus, lenticonus,spherophakia)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study was a randomized, double-blind, placebo-controlled, multicenter, superiority design, phase III clinical trial to compare the efficacy and safety of two low-concentration atropine sulfate eye drops versus placebo in delaying myopia progression in children.
The 3 groups in the trial
- Experimental group 1Treatment being tested
1 drop each time, once every night at bedtime
Treatment: Lower dose atropine sulfate eye drops and Low dose atropine sulfate eye drops
- Experimental group 2Treatment being tested
1 drop each time, once every night at bedtime
Treatment: Low dose atropine sulfate eye drops
- control groupTreatment being tested
1 drop each time, once every night at bedtime
Treatment: placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops in Slowing the Progression of Myopia in Children
- Record updated
- 30 July 2025